Back to results
US 2026/0265389 A1Published application
Engineered bispecific molecules and methods of use
AssigneeCantai Therapeutics Inc.
InventorGeeta Vemuri
Life of this patent
Estimating the term…
Abstract
Provided herein are bispecific molecules and methods of treating using the bispecific molecules, wherein the bispecific molecules comprise a first binding domain and a second binding domain, wherein the first binding domain binds TL1A, a variant thereof or a functional fragment thereof, and wherein the second binding domain binds any one of IL-6R, IL-6, IL-12, IL-23, an IL-17 family cytokine, IL-17R, a variant thereof, and a functional fragment thereof.
Claims20
An IgG antibody construct comprising:
- a TL1A binding region that binds an epitope on TL1A, a variant thereof or a functional fragment thereof, and
- an IL-23 binding region that binds an epitope on IL-23, a variant thereof or a functional fragment thereof,
- wherein:
- said TL1A binding region comprises a TL1A binding heavy chain variable domain and a TL1A binding light chain variable domain,
- at least one amino acid modification in said TL1A binding heavy chain variable region and/or said TL1A binding light chain variable region, and
- said amino acid modification changes an isoelectric point (pI) of said IgG antibody construct relative to a pI of a corresponding IgG antibody construct prior to said amino acid modification, thereby resulting in pH-dependent binding activity for said TL1A in said IgG antibody construct, as measured by surface plasmon resonance spectroscopy.
3 more elements
An IgG antibody construct comprising:
- a TL1A binding region that binds an epitope on TL1A, a variant thereof or a functional fragment thereof, and
- a second binding region that binds an epitope on IL-12p40, IL-12p35, IL-6R, IL-6, IL-17 family cytokine, IL-17R, a variant thereof or a functional fragment thereof,
- wherein:
- said TL1A binding region comprises a TL1A binding heavy chain variable domain and a TL1A binding light chain variable domain, and
- at least one amino acid modification in said TL1A binding heavy chain variable domain and/or said TL1A binding light chain variable domain, and
- said amino acid modification changes an isoelectric point (pI) of said IgG antibody construct relative to a pI of a corresponding IgG antibody construct prior to said amino acid modification, thereby resulting in pH-dependent binding activity for said TL1A in said IgG antibody construct, as measured by surface plasmon resonance spectroscopy.
3 more elements
Dependencies are inferred from the claim text.